DMI BioSciences Migrates to Fitzsimons

The new 25,000 square foot Bioscience East building at Fitzsimons signed its first tenant, DMI BioSciences, Inc.. DMI will occupy 15,000 sq. ft. of East on 1 May 2006. With two ongoing Phase II clinical trials DMI is among the more advanced companies residing in the bioscience park campus.

DMI is a privately-held biopharmaceutical company that discovers and develops small molecule and peptide-based pharmaceuticals and biomarkers for acute and chronic inflammation. DMI focuses on immunologic, vascular and CNS diseases, including acute coronary syndrome, multiple sclerosis, Alzheimer's disease, asthma and cancer. DMI has two wholly-owned subsidiaries in the United Kingdom, DMI BioSciences (UK), Ltd., and DMI Synthesis (UK), Ltd., including facilities at Imperial House, Imperial Park, Newport, South Wales, where the Company conducts a substantial amount of its operations.